Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade

Lise Aagaard1, Erik Wind Hansen, Ebba Holme Hansen

  • 1Department of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark. laa@farma.ku.dk

Insights

Paediatric immunization in Denmark led to many reported adverse events (AEFIs), but most were not serious. This study analyzed AEFIs in children to understand vaccine safety risks.

Area of Science:

  • Pediatric medicine
  • Pharmacovigilance
  • Immunization safety

Background:

  • Paediatric immunization is crucial for preventing serious diseases.
  • Vaccine administration carries risks of adverse drug reactions (ADRs), some serious.
  • Existing evidence on ADRs in childhood immunization programs is contradictory.

Purpose of the Study:

  • To characterize reported adverse events following immunization (AEFIs) in Danish children.
  • To analyze the types, frequency, and seriousness of AEFIs in a pediatric population.

Main Methods:

  • Analysis of AEFIs reported to the Danish Medicines Agency (DKMA) between 1998-2007.
  • Inclusion of children aged 0-17 years.
  • Categorization of AEFIs by time, age, gender, vaccine, and seriousness.

Main Results:

  • DKMA received 1,365 reports covering 2,600 AEFIs; 60% of all reported pediatric adverse events.
  • One-third of AEFIs were serious, with two reported deaths; serious AEFIs remained constant annually.
  • 80% of AEFIs occurred in children aged 0-2 years; common AEFIs included general disorders, skin, and nervous system disorders.

Conclusions:

  • A significant number of AEFIs were reported following pediatric immunization in Denmark.
  • The majority of reported AEFIs were non-serious.
  • Nervous system disorders constituted the largest share of serious AEFIs.
Abstract

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Vaccinations01:51

Vaccinations

Overview
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Allergic Reactions02:06

Allergic Reactions

Overview